Chadwick Jeremy G, Chief Operating Officer of Kymera Therapeutics Inc ($KYMR), sold about $2.7 million worth of company shares across 11 open market transactions in the last 365 days. His most recent sale occurred on March 11, 2026. These sales rank 2,884th among 11,678 individual insiders by total value, below the average of $8.6 million per seller and 6.4 transactions. He made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 1100 | $86.05 | 61,202.0000 | 87,300,286 | 1.77% | 0.00% |
| April 1, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 13540 | $85.41 | 62,302.0000 | 87,300,286 | 17.85% | 0.02% |
| April 1, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | M | Common Stock | 14640 | $29.64 | 75,842.0000 | 87,300,286 | 23.92% | 0.02% |
| March 31, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 7600 | $85.38 | 61,202.0000 | 87,300,286 | 11.05% | 0.01% |
| March 31, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | M | Common Stock | 7600 | $29.64 | 68,802.0000 | 87,300,286 | 12.42% | 0.01% |
| April 1, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | M | Stock Option (Right to Buy) | 14640 | $0.00 | 68,633.0000 | 87,300,286 | 17.58% | 0.02% |
| March 31, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | M | Stock Option (Right to Buy) | 7600 | $0.00 | 83,273.0000 | 87,300,286 | 8.36% | 0.01% |
| March 25, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 24727 | $80.26 | 61,202.0000 | 87,300,286 | 28.78% | 0.03% |
| March 23, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | M | Common Stock | 84400 | $29.64 | 152,452.0000 | 87,300,286 | 124.02% | 0.10% |
| March 23, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | M | Stock Option (Right to Buy) | 84400 | $0.00 | 115,600.0000 | 87,300,286 | 42.20% | 0.10% |
| March 25, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | M | Stock Option (Right to Buy) | 24727 | $0.00 | 90,873.0000 | 87,300,286 | 21.39% | 0.03% |
| March 23, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 22756 | $76.73 | 129,696.0000 | 87,300,286 | 14.93% | 0.03% |
| March 23, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 52975 | $77.21 | 76,721.0000 | 87,300,286 | 40.85% | 0.06% |
| March 23, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 8214 | $78.40 | 68,507.0000 | 87,300,286 | 10.71% | 0.01% |
| March 23, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 6105 | $79.87 | 62,402.0000 | 87,300,286 | 8.91% | 0.01% |
| March 23, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 1200 | $80.05 | 61,202.0000 | 87,300,286 | 1.92% | 0.00% |
| March 25, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | M | Common Stock | 24727 | $29.64 | 85,929.0000 | 87,300,286 | 40.40% | 0.03% |
| March 11, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | M | Stock Option (Right to Buy) | 20000 | $0.00 | 60,548.0000 | 87,300,286 | 24.83% | 0.02% |
| March 11, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 1765 | $82.13 | 92,045.0000 | 87,300,286 | 1.88% | 0.00% |
| March 11, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 11111 | $83.72 | 68,052.0000 | 87,300,286 | 14.04% | 0.01% |
| March 11, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 12882 | $83.10 | 79,163.0000 | 87,300,286 | 14.00% | 0.01% |
| March 11, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | M | Common Stock | 20000 | $43.50 | 93,810.0000 | 87,300,286 | 27.10% | 0.02% |
| March 4, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 2017 | $85.04 | 75,318.0000 | 87,300,286 | 2.61% | 0.00% |
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | A | Common Stock | 12575 | $0.00 | 79,768.0000 | 87,300,286 | 18.71% | 0.01% |
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 549 | $87.75 | 79,219.0000 | 87,300,286 | 0.69% | 0.00% |
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 383 | $88.50 | 78,836.0000 | 87,300,286 | 0.48% | 0.00% |
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 1107 | $89.66 | 77,729.0000 | 87,300,286 | 1.40% | 0.00% |
| March 4, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 394 | $84.00 | 77,335.0000 | 87,300,286 | 0.51% | 0.00% |
| March 4, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 1150 | $85.78 | 74,168.0000 | 87,300,286 | 1.53% | 0.00% |
| March 4, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 358 | $86.62 | 73,810.0000 | 87,300,286 | 0.48% | 0.00% |
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | A | Stock Option (Right to Buy) | 25150 | $0.00 | 25,150.0000 | 87,300,286 | 9999.99% | 0.03% |
| May 23, 2025 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 2575 | $29.30 | 66,420.0000 | 75,043,991 | 3.73% | 0.00% |
| March 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | A | Common Stock | 25000 | $0.00 | 69,183.0000 | 75,043,991 | 56.58% | 0.03% |
| March 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | A | Stock Option (Right to Buy) | 50000 | $0.00 | 50,000.0000 | 75,043,991 | 9999.99% | 0.07% |
| March 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 252 | $31.00 | 67,800.0000 | 75,043,991 | 0.37% | 0.00% |
| March 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 1131 | $30.33 | 68,052.0000 | 75,043,991 | 1.63% | 0.00% |
| May 23, 2024 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | S | Common Stock | 2575 | $34.99 | 44,183.0000 | 58,365,499 | 5.51% | 0.00% |
| March 1, 2024 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | A | Stock Option (Right to Buy) | 80548 | $0.00 | 80,548.0000 | 58,365,499 | 9999.99% | 0.14% |
| March 1, 2024 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | A | Common Stock | 13425 | $0.00 | 46,758.0000 | 58,365,499 | 40.28% | 0.02% |
| May 22, 2023 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | A | Stock Option (Right to Buy) | 200000 | $0.00 | 200,000.0000 | 53,933,229 | 9999.99% | 0.37% |
| May 22, 2023 | Kymera Therapeutics, Inc. | $KYMR | Chadwick Jeremy G | Chief Operating Officer | A | Common Stock | 33333 | $0.00 | 33,333.0000 | 53,933,229 | 9999.99% | 0.06% |